{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:35:27Z","timestamp":1792654527970,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:00:00Z","timestamp":1573776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001009","name":"Bristol-Myers Squibb Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To evaluate clinical outcomes after either immediate or deferred initiation of antiretroviral therapy in HIV-1-infected patients, presenting late with pneumocystis pneumonia (PCP) or toxoplasma encephalitis (TE).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Phase IV, multicenter, prospective, randomized open-label clinical trial. Patients were randomized into an immediate therapy arm (starting antiretroviral therapy (ART) within 7\u00a0days after initiation of OI treatment) versus a deferred arm (starting ART after completing the OI-therapy). All patients were followed for 24\u00a0weeks. The rates of clinical progression (death, new or relapsing opportunistic infections (OI) and other grade 4 clinical endpoints) were compared, using a combined primary endpoint. Secondary endpoints were hospitalization rates after completion of OI treatment, incidence of immune reconstitution inflammatory syndrome (IRIS), virologic and immunological outcome, adherence to proteinase-inhibitor based antiretroviral therapy (ART) protocol and quality of life.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>61 patients (11 patients suffering TE, 50 with PCP) were enrolled. No differences between the two therapy groups in all examined primary and secondary endpoints could be identified: immunological and virologic outcome was similar in both groups, there was no significant difference in the incidence of IRIS (11 and 10 cases), furthermore 9 events (combined endpoint of death, new\/relapsing OI and grade 4 events) occurred in each group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In summary, this study supports the notion that immediate initiation of ART with a ritonavir-boosted proteinase-inhibitor and two nucleoside reverse transcriptase inhibitors is safe and has no negative effects on incidence of disease progression or IRIS, nor on immunological and virologic outcomes or on quality of life.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12981-019-0250-2","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T06:02:34Z","timestamp":1573797754000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study)"],"prefix":"10.1186","volume":"16","author":[{"name":"the IDEAL study group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0983-4234","authenticated-orcid":false,"given":"Guido","family":"Sch\u00e4fer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keikawus","family":"Arasteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Sch\u00fcrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes R.","family":"Bogner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Faetkenheuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Rockstroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartwig","family":"Klinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"H\u00e4rter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"St\u00f6hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Degen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Freiwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"H\u00fcfner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Schulze zur Wiesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marylyn","family":"Addo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar W.","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van Lunzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schmiedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,15]]},"reference":[{"key":"250_CR1","unstructured":"World health organization (WHO). Fact sheet about HIV\/AIDS, update November 2017. http:\/\/www.who.int\/mediacentre\/factsheets\/fs360\/en\/. Accessed 06 Jan 2018."},{"issue":"3","key":"250_CR2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1080\/09540120802183537","volume":"21","author":"A Adler","year":"2009","unstructured":"Adler A, Mounier-Jack S, Coker RJ. Late diagnosis of HIV in Europe: definitional and public health challenges. AIDS Care. 2009;21(3):284\u201393.","journal-title":"AIDS Care"},{"issue":"3","key":"250_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/QAI.0b013e318186eabc","volume":"49","author":"V Borghi","year":"2008","unstructured":"Borghi V, Girardi E, Bellelli S, Angeletti C, Mussini C, Porter K, Esposito R. Late presenters in an HIV surveillance system in Italy during the period 1992-2006. J Acquir Immune Defic Syndr. 2008;49(3):282\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"250_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1097\/00002030-200209270-00012","volume":"16","author":"J Castilla","year":"2002","unstructured":"Castilla J, Sobrino P, de la Fuente L, Noguer I, Guerra L, Parras F. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. AIDS. 2002;16:1945\u201351.","journal-title":"AIDS"},{"issue":"4","key":"250_CR5","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/00126334-200408010-00009","volume":"36","author":"E Girardi","year":"2004","unstructured":"Girardi E, Aloisi MS, Arici C, Pezzotti P, Serraino D, Balzano R, Vigevani G, Alberici F, Ursitti M, D\u2019Alessandro M, d\u2019Arminio Monforte A, Ippolito G, for the IcoNA Behavioural Epidemiology Study Group. Delayed presentation and late testing for HIV: demographic and behavioural risk factors in a multicenter study in Italy. J Acquir Immune Defic Syndr. 2004;36(4):951\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"250_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s15010-016-0880-4","volume":"44","author":"G Sch\u00e4fer","year":"2016","unstructured":"Sch\u00e4fer G, Kreuels B, Schmiedel S, Hertling S, H\u00fcfner A, Degen O, van Lunzen J, Schulze zur Wiesch J. High proportion of HIV late presenters at an academic tertiary care center in northern Germany confirms the results of several cohorts in Germany. Infection. 2016;44:347\u201352.","journal-title":"Infection"},{"issue":"6","key":"250_CR7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1468-1293.2008.00566.x","volume":"9","author":"M Wolbers","year":"2008","unstructured":"Wolbers M, Bucher HC, Furrer H, Rickenbach M, Cavassini M, Weber R, Schmid P, Bernasconi E, Hirschel B, Battegay M, Swiss HIV Cohort Study. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. HIV Med. 2008;9(6):397\u2013405.","journal-title":"HIV Med"},{"issue":"3","key":"250_CR8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1468-1293.2011.00958.x","volume":"12","author":"A Zoufaly","year":"2012","unstructured":"Zoufaly A, An der Heiden M, Marcus U, Hoffmann C, Stellbrink H, Voll L, van Lunzen J, Hamouda O, ClinSurv Study Group. Late presentation for HIV diagnosis and care in Germany. HIV Med. 2012;12(3):172\u201381.","journal-title":"HIV Med"},{"issue":"10","key":"250_CR9","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1258\/095646205774357262","volume":"16","author":"J Br\u00e4nnstr\u00f6m","year":"2005","unstructured":"Br\u00e4nnstr\u00f6m J, Akerlund B, Arneborn M, Blaxhult A, Giesecke J. Patients unaware of their HIV infection until AIDS diagnosis in Sweden 1996\u20132002\u2014a remaining problem in the highly active antiretroviral therapy era. Int J STD AIDS. 2005;16(10):702\u20136.","journal-title":"Int J STD AIDS"},{"key":"250_CR10","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1097\/QAD.0b013e328314b5f1","volume":"22","author":"C Mussini","year":"2008","unstructured":"Mussini C, Manzardo C, Johnson M, et al. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS. 2008;22:2461\u20139.","journal-title":"AIDS"},{"issue":"Suppl 1","key":"250_CR11","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/01.qai.0000286597.57066.2b","volume":"46","author":"E Girardi","year":"2007","unstructured":"Girardi E, Sabin CA, Monforte AD. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr. 2007;46(Suppl 1):S3\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"250_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1468-1293.2007.00443.x","volume":"8","author":"W St\u00f6hr","year":"2007","unstructured":"St\u00f6hr W, Dunn D, Porter K, Hill T, Gazzard B, Walsh J, Gilson R, Easterbrook P, Fisher M, Johnson M, Delpech V, Phillips A, Sabin C, UK CHIC Study. CD4 cell count and initiation of antiretroviral therapy: trends in seven UK centres, 1997\u20132003. HIV Med. 2007;8(3):135\u201341.","journal-title":"HIV Med"},{"issue":"1","key":"250_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1468-1293.2010.00857.x","volume":"12","author":"A Antinori","year":"2011","unstructured":"Antinori A, Coenen T, Costagiola D, European Late Presenter Consensus Working Group, et al. Late presentation of HIV infection: a consensus definition. HIV Med. 2011;12(1):61\u20134.","journal-title":"HIV Med"},{"issue":"Suppl 1","key":"250_CR14","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1097\/01.qai.0000286599.38431.ef","volume":"46","author":"C Manzardo","year":"2007","unstructured":"Manzardo C, Zaccarelli M, Ag\u00fcero F, Antinori A, Mir\u00f3 JM. Optimal timing and best antiretroviral regimen in treatment-na\u00efve HIV-infected individuals with advanced disease. J Acquir Immune Defic Syndr. 2007;46(Suppl 1):S9\u201318.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"250_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s15010-018-1167-8","volume":"46","author":"L Deen","year":"2018","unstructured":"Deen L, Cowan S, Wejse C, Petersen JH, Norredam M, ESCMID Study Group for Infections in Travellers and Migrants. Refugees and family-reunified immigrants have a high incidence of HIV diagnosis and late presentation compared with Danish born: a nationwide register-based cohort study. Infection. 2018;46(5):659\u201367.","journal-title":"Infection"},{"key":"250_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1258\/ijsa.2008.008449","volume":"20","author":"JWT Elston","year":"2009","unstructured":"Elston JWT, Thacker H. Immune reconstitution inflammatory syndrome. Int J STD AIDS. 2009;20:221\u20134.","journal-title":"Int J STD AIDS"},{"key":"250_CR17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1258\/0956462001916407","volume":"11","author":"JS Hocking","year":"2000","unstructured":"Hocking JS, Rodger AJ, Rhodes DG, Crofts N. Late presentation of HIV infection associated with prolonged survival following AIDS diagnosis: characteristics of individuals. Int J STD AIDS. 2000;11:503\u20138.","journal-title":"Int J STD AIDS"},{"key":"250_CR18","unstructured":"International Network for the Study of HIV-associated IRIS (INSHI). Definition IRIS. http:\/\/www.inshi.umn.edu\/definitions\/General_IRIS\/home.html."},{"issue":"7","key":"250_CR19","doi-asserted-by":"publisher","first-page":"e11416","DOI":"10.1371\/journal.pone.0011416","volume":"5","author":"PM Grant","year":"2010","unstructured":"Grant PM, Komarow L, Andersen J, et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PLoS ONE. 2010;5(7):e11416.","journal-title":"PLoS ONE"},{"key":"250_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1742-6405-6-16","volume":"6","author":"DM Murdoch","year":"2009","unstructured":"Murdoch DM, Suchard MS, Venter WDF, Mhlangu P, Ottinger JS, Feldman C. Polychromatic immunophenotypic characterization of T cell profiles among HIV-infected patients experiencing immune reconstitution inflammatory syndrome (IRIS). AIDS Res Ther. 2009;6:16.","journal-title":"AIDS Res Ther"},{"key":"250_CR21","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1086\/503903","volume":"42","author":"J Roberston","year":"2006","unstructured":"Roberston J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis. 2006;42:1639\u201346.","journal-title":"Clin Infect Dis"},{"issue":"Suppl","key":"250_CR22","first-page":"S9","volume":"46","author":"A Zolopa","year":"2009","unstructured":"Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression\/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE. 2009;46(Suppl):S9\u201318.","journal-title":"PLoS ONE"},{"issue":"1","key":"250_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/jac\/dkn169","volume":"62","author":"M Battegay","year":"2008","unstructured":"Battegay M, Fehr J, Fl\u00fcckiger U, Elzi L. Antiretroviral therapy of late presenters with advanced HIV disease. J Antimicrob Chemother. 2008;62(1):41\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"250_CR24","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/j.1469-0691.2012.03991.x","volume":"19","author":"C Manzardo","year":"2013","unstructured":"Manzardo C, Esteve A, Ortega N, et al. Optimal timing for initiation of highly active antiretroviral therapy in treatment-na\u00efve HIV-I-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort. Clin Microb Inf. 2013;19:646\u201353.","journal-title":"Clin Microb Inf"},{"issue":"1","key":"250_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/QCO.0b013e3283420f76","volume":"24","author":"SD Lawn","year":"2011","unstructured":"Lawn SD, T\u00f6r\u00f6k ME, Wood R. Optimal time to start antiretroviral therapy during HIV-associated opportunistic infections. Curr Opin Infect Dis. 2011;24(1):34\u201342.","journal-title":"Curr Opin Infect Dis"},{"issue":"8","key":"250_CR26","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1056\/NEJMoa0905848","volume":"362","author":"SS Abdool Karim","year":"2010","unstructured":"Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362(8):697\u2013706.","journal-title":"N Engl J Med"},{"key":"250_CR27","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1097\/QAD.0000000000000456","volume":"28","author":"S Lodi","year":"2014","unstructured":"The HIV-CAUSAL-Collaboration, Lodi S, del Amo J, et al. Opportunistic infections and AIDS malignancies early after initiation combination antiretroviral therapy in high-income countries. AIDS. 2014;28:2461\u201373.","journal-title":"AIDS"},{"key":"250_CR28","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa1312884","volume":"370","author":"DR Boulware","year":"2014","unstructured":"Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med. 2014;370:2487\u201398.","journal-title":"N Engl J Med"},{"key":"250_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009012.pub2","author":"B Njei","year":"2013","unstructured":"Njei B, Kongnyuy EJ, Kumar S, et al. Optimal timing for antiretroviral therapy initiation in patients with HIV infection and concurrent cryptococcal meningitis. Cochrane Database Syst Rev. 2013. https:\/\/doi.org\/10.1002\/14651858.CD009012.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"250_CR30","unstructured":"European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV-infected adults in Europe. 2011. http:\/\/www.eacsociety.org\/files\/2011_eacsguidelines-v6.0-english_oct.pdf."},{"key":"250_CR31","unstructured":"Services, DHHS: US Department of Health and Human. Guidelines for the clinical management and treatment of HIV-infected adults in Europe. 2011. https:\/\/aidsinfo.nih.gov\/contentiles\/AdultandAdolescentGL002111.pdf."},{"key":"250_CR32","first-page":"323","volume":"53","author":"JM Molina","year":"2010","unstructured":"Molina JM, Andrade-Villanueva J, et al. Once-daily atazanavir\/ritonavir compared with twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral naive HIV-1-infected patients: 96\u00a0week efficacy and safety results from the CASTLE study. J AIDS. 2010;53:323\u201332.","journal-title":"J AIDS"},{"key":"250_CR33","first-page":"161","volume":"47","author":"DR Malan","year":"2008","unstructured":"Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J AIDS. 2008;47:161\u20137.","journal-title":"J AIDS"},{"key":"250_CR34","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","volume":"365","author":"DV Havlir","year":"2011","unstructured":"Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365:1482\u201391.","journal-title":"N Engl J Med"},{"key":"250_CR35","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","volume":"365","author":"F-X Blanc","year":"2011","unstructured":"Blanc F-X, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471\u201381.","journal-title":"N Engl J Med"},{"key":"250_CR36","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1056\/NEJMe1109546","volume":"365","author":"ME T\u00f6r\u00f6k","year":"2011","unstructured":"T\u00f6r\u00f6k ME, Farrar JJ. When to start antiretroviral therapy in HIV-associated tuberculosis. N Engl J Med. 2011;365:1538\u201340.","journal-title":"N Engl J Med"},{"key":"250_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009012.pub3","author":"I Eshun-Wilson","year":"2018","unstructured":"Eshun-Wilson I, Okwen MP, Richardson M, Bicanic T. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis. Cochrane Database Syst Rev. 2018. https:\/\/doi.org\/10.1002\/14651858.CD009012.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"250_CR38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s15010-017-1111-3","volume":"46","author":"A Rostami","year":"2018","unstructured":"Rostami A, Karanis P, Fallahi S. Advances in serological, imaging techniques and molecular diagnosis of Toxoplasma gondii infection. Infection. 2018;46(3):303\u201315.","journal-title":"Infection"},{"key":"250_CR39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000487713","volume":"96","author":"HJF Salzer","year":"2018","unstructured":"Salzer HJF, Sch\u00e4fer G, Hoenigl M, G\u00fcnther G, Hoffmann C, Kalsdorf B, Alanio A, Lange C. Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia. Respiration. 2018;96:52\u201365.","journal-title":"Respiration"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-019-0250-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12981-019-0250-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-019-0250-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T09:44:49Z","timestamp":1612345489000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-019-0250-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,15]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["250"],"URL":"https:\/\/doi.org\/10.1186\/s12981-019-0250-2","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,15]]},"assertion":[{"value":"13 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participating sites had local ethical approval according to national laws. All subjects provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All mentioned authors gave their consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Johannes R. Bogner received honorary for advisory boards and lecturing from AbbVie, ViiV, MSD, Gilead, Janssen, BMS, Hexal. Christian Hoffmann has received honoraria for lecturing, advisory boards and travelling grants and research grants from AbbVie, Bristol Myers-Squibb, Boehringer-Ingelheim, Gilead Sciences, HEXAL, Hormosan, Janssen-Cilag, MSD, Teratech and ViiV Healthcare. Gerd Faetkenheuer received lecture fees, honorary for advisory boards, and travel and research grants: Bristol Myers Squibb, Gilead, Merck Sharp & Dohme. Jan van Lunzen has received honoraria for lecturing, advisory boards and travelling grants from AbbVie, Bristol Myers-Squibb, Boehringer-Ingelheim, Gilead Sciences, HEXAL, Janssen-Cilag, MSD, Teratech and ViiV Healthcare. Christoph Stephan received financial support, related to scientific projects by MSD, BMS, AbbVie and received honorary for lectures or scientific advisory boards from: Abbott, BMS, ViiV, Gilead, Janssen, Roche. Juergen Rockstroh has received honoraria for consulting or speaking at educational events from Abbvie, BMS, Gilead, Merck, Janssen and ViiV. Olaf Degen received honoraria for lecturing, advisory boards and travelling grants from ViiV, GSK, Gilead, BMS, Janssen-Cilag. Matthias Stoll received honoraria as advisor, lecturer or funding of studies by Abbott, Abbvie, Boehringer-Ingelheim, Bristol-Myers-Squibb, Gilead, Glaxo-Smith-Kline, Hexal, Hormosan, Janssen-Cilag, Merck, Sharp & Dohme, Novartis, Pfizer, Roche, Tibotec, ViiV, Viro-Pharmaceuticals. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}